SCHEMBL6088620

SCHEMBL6088620

CN1CCN(CCNc2ccc3c(c2)COC3=C2C(=O)Nc3cc(F)ccc32)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 6/20 0.42
PDGFRB P09619 8/20 0.40
KDR P35968 8/20 0.40
KIT P10721 6/20 0.40
FGFR1 P11362 3/20 0.38
FLT3 P36888 2/20 0.38
KCNH2 Q12809 2/20 0.38
CHEK1 O14757 1/20 0.38
ABL1 P00519 1/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
CSF1R P07333 1/20 0.38
RET P07949 1/20 0.38
PHKG2 P15735 1/20 0.38
FLT1 P17948 1/20 0.38
FGFR3 P22607 1/20 0.38
AXL P30530 1/20 0.38
ABL2 P42684 1/20 0.38
PTK2 Q05397 1/20 0.38
PTK2B Q14289 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6088617 1.00 MAPK14 (0.42) MAPK14PDGFRBKDRKITFGFR1
SCHEMBL6087516 0.94 PDGFRB (0.44) MAPK14PDGFRBKDRKITFGFR1
SCHEMBL6087512 0.94 PDGFRB (0.44) MAPK14PDGFRBKDRKITFGFR1
SCHEMBL6087899 0.93 PDGFRB (0.43) MAPK14PDGFRBKDRKITFGFR1
SCHEMBL6087907 0.93 PDGFRB (0.43) MAPK14PDGFRBKDRKITFGFR1
SCHEMBL6087057 0.92 MAPK14 (0.51) MAPK14PDGFRBKDRKITFGFR1
SCHEMBL6087065 0.92 MAPK14 (0.51) MAPK14PDGFRBKDRKITFGFR1
SCHEMBL6086159 0.90 PDGFRB (0.39) MAPK14PDGFRBKDRKITFGFR1
SCHEMBL6086166 0.90 PDGFRB (0.39) MAPK14PDGFRBKDRKITFGFR1
SCHEMBL6087759 0.88 PDGFRB (0.48) MAPK14PDGFRBKDRKITFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490356-B1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN INC (US) 2013-02-27 EP claimed
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2004-01-29 US claimed
EP-1490356-B1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN INC (US) 2013-02-27 EP disclosed
US-7060844-B2 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-06-13 US disclosed
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-01-05 US disclosed
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2004-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 MAPK14 186/4885PDGFRB 502/4885KDR 320/4885
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 MAPK14 191/4885PDGFRB 490/4885KDR 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.